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Podophyllotoxin (PT) and its clinically used analogues are known to be powerful antitumour agents.
These compounds contain a trans fused strained g-lactone system, a feature that correlates to the process
of epimerisation, whereby the trans g-lactone system of ring D opens and converts to the more ther-
modynamically stable cis epimer. Since these cis epimers are known to be either less active or lacking
antitumour activity, epimerisation is an undesirable feature from a chemotherapeutic point of view. To
circumvent this problem, considerable efforts have been reported, amongst which is the synthesis of
azapodophyllotoxins where the stereocentres at C2 and C3 are removed in order to preclude epimer-
isation. Herein we report the identiﬁcation of a novel C3 hydroxy, cis-selective g-lactone conﬁguration of
ring C in the azapodophyllotoxin scaffold, through an efﬁcient stereoselective multicomponent reaction
(MCR) involving ﬂuorinated and non-ﬂuorinated aldehydes. This conﬁguration releases the highly
strained trans g-lactone system in podophyllotoxin analogues into the more thermodynamically stable
cis g-lactone motif and yet retains signiﬁcantly potent activity. These compounds were evaluated against
the human cancer lines MCF-7 and 22Rv1 in vitro. Fourteen out of the seventeen tested compounds
exhibited sub-micromolar activity with IC50 values in the range of 0.11e0.91 mM, which is comparable
and in some cases better than the activity proﬁle of etoposide in this assay. Interestingly, we obtained
strong evidence from spectroscopic and X-ray data analyses that the previously reported structure of
similar analogues is not accurate. Molecular modelling performed using the podophyllotoxin binding site
on b tubulin revealed a novel binding mode of these analogues. Furthermore, sub-cellular study of our
compounds using immunolabelling and confocal microscopy analyses showed strong microtubule
disruptive activity, particularly in dividing cells.
© 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Natural products are known to be evolutionary privileged
structures. Historically, they have been an invaluable source of new
pharmaceuticals. Almost 60% of anticancer drugs are derived from
or related to natural products [1,2]. Among these podophyllotoxin
(PT) (1, Fig. 1) is a naturally occurring cyclolignan compound ob-
tained from podophyllum peltatum and related species [3]. PT and its
derivatives exhibit anticancer, antiviral and insecticidal activities
due to their strong microtubule destabilising activity [4e7]. Using
PT as lead in anticancer drug discovery resulted in the developmentll).
r Masson SAS. This is an open acceof semi-synthetic analogues such as etoposide (2) and teniposide
(3) (Fig. 1), which are currently used either alone or in combination
with other therapies for the treatment of a variety of malignancies
including lung and testicular cancers, lymphoma, non-lymphocytic
leukaemia, glioblastoma multiforme and childhood acute lym-
phocytic leukaemia [8]. Despite this there are some drawbacks
associated with these agents such as the development of resistance,
poor water solubility, metabolic inactivation and side effects like
myelosuppression, neutropenia and nausea [8]. For these reasons,
the search for new more effective podophyllotoxin analogues re-
mains a highly valuable objective.
The PT structure was ﬁrst elucidated in the 1930s and features
four contiguous chiral centres on ring C (C1 through C4) (Fig. 1).
However, due to its structural complexity, the total synthesis of
podophyllotoxin analogues is greatly hindered and most of the SARss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Structure of podophyllotoxin (1) and its mimetic scaffolds; etoposide (2) teniposide (3) and 4-azapodophyllotoxin (4).
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rivatives rather than novel chemical entities. The stereochemical
intricacy and the associated tedious synthetic approaches, together
with the liability of in vivo epimerisation and formation of the less
potent cis lactone metabolite, have fuelled further investigations
into the necessity of simplifying the PT structure and improving its
potencyetoxicity proﬁles. Such efforts resulted in the discovery of
4-azapodophyllotoxins (APT, 4) (Fig. 1) [9,10].
Lactone epimerisation is a particularly problematic feature of
podophyllotoxin analogues. Epimerisation is a metabolic inactiva-
tion process, whereby the trans g-lactone ring is converted to the cis
isomer. Notably, picropodophyllin, the cis isomer of podophyllo-
toxin, is 100-fold less active [11]. In order to avoid the C2 epime-
rization and/or the trans g-lactone ring opening, a number of
approaches have been proposed. These included the replacement of
the trans g-lactone with furan, thiolan or cyclopentane rings [9].
Another strategy described the preparation of derivatives
substituted at the C2 position [12e14]. In addition, the synthesis of
analogues having a six-membered lactone ring was suggested
because increasing the lactone ring size was assumed to give access
to more stable isomers [15]. However to date none of these stra-
tegies has been successful in producing comparable activity to the
trans g-lactone compounds. The 4-azapodophyllotoxin (APT) scaf-
fold was another alternative approach and during the last two
decades there has been considerable effort towards its synthesis
and antitumour evaluation. Classically, a three-component reaction
is used to prepare 4-azapodophyllotoxin analogues (4) for its high
synthetic efﬁciency and more importantly for reducing the number
of stereocentres by removing the chirality at C2 and C3 and
replacing them by a double bond [16].
The use of multicomponent reaction (MCR) approaches to pre-
pare APT has allowed medicinal chemists to generate a diverse li-
brary of podophyllotoxin mimetics. The substantial advantages of
these compounds include: retention of a comparable destabilisa-
tion of tubulin polymerisation as that of podophyllotoxin; consid-
erable synthetic feasibility; provision of the opportunity to explore
the effect of different structural modiﬁcations on antimitoticactivity; and most importantly, a plausible solution for the problem
of epimerisation that plagued podophyllotoxin and its stereo-
chemically similar analogues, simply by removing the chirality at
the stereocentres at C2 and C3 [9,10]. Several APT derivatives were
reported to be potent tumour inhibitors and vascular disrupting
agents [17,18].
In a recently published study, the potential antineoplastic ac-
tivity of 1,10-phenanthroline was utilised to replace rings A and B of
azapodophyllotoxin in order to combine the pharmacological
properties of both these chromophores [19]. As a continuation of
the efforts on structural modiﬁcation of the azapodophyllotoxin
scaffold (4), we were interested to further explore the impact of
introducing different ﬂuorinated moieties into ring E, on the ac-
tivity of these compounds. Introduction of ﬂuorinated substituents
into drug candidates can provide unique protein-ligand in-
teractions owing to the special combination of electronegativity,
size and lipophilicity of ﬂuorine atoms. These factors can have a
substantial impact on molecular conformation, which in turn affect
the binding afﬁnity to the target protein and can also greatly affect
physico-chemical and pharmaceutical properties [20].
2. Results and discussion
2.1. Ring E modiﬁcations of the 1,10 phenanthroline 4-
azapodophyllotoxin analogues
Fluorination is often used in drug design to form novel in-
teractions unavailable to the parent species due to the unique
properties (size, electronegativity and lipophilicity) of the ﬂuorine
atom [20]. In an attempt to expand the range of possible ring E
modiﬁcations in the [1,10]-phenanthroline 4-azapodophyllotoxin
scaffold [19], we explored the use of various ﬂuorinated and non-
ﬂuorinated aromatic aldehydes (7a-q) in the multicomponent re-
action (MCR) process.
We followed the reported azapodophyllotoxin procedure, i.e.
one-pot, three-component reaction of 1,10 phenanthroline amine
(5), tetronic acid (6) and different ﬂuorinated and non-ﬂuorinated
S. Kandil et al. / European Journal of Medicinal Chemistry 110 (2016) 311e325 313aldehydes (7a-q) as shown in Scheme 1 [19]. To our surprise the
spectroscopic data we generated did not agree with the expected
previously reported formula A, Scheme 1. Further analysis of the
spectroscopic data together with an X-ray crystal structure study
(Section 2.2) led us to identify the unexpected and novel C3 hy-
droxy (podophyllotoxin numbering system), cis-selective g-lactone
conﬁguration of ring C (formula B), instead of the previously re-
ported formula A (Scheme 1).
In our further ring Emodiﬁcation efforts, bulkier and more rigid
substituents were introduced into ring E of compounds 8p and 8q
in order to investigate their effect on the cytotoxic activity proﬁle.
The target compounds (8a-q) were prepared by reacting 1,10 phe-
nanthroline amine (5), tetronic acid (6) and various ﬂuorinated and
non-ﬂuorinated aldehydes (7a-q) in reﬂuxing ethanol. In all cases
the reaction proceeded smoothly and the isolated products were
recrystallised frommethanol to afford the pure compounds (8a-q).
Spectroscopic analysis of our products revealed that the ex-
pected structure from the closely related analogues of the previous
study i.e. formula A (Scheme 1) [19] was not entirely accurate but
rather another unexpected structure represented by the general
formula B (Scheme 1 and 2) was obtained. The proton NMR spectra
of all our products showed an extra hydrogen signal at around
d 3.50 (assigned to CH12a H) and another D2O exchangeable proton
signal at around d 6.00 (assigned to CH9a OH), combined with the
presence of a tertiary carbon signal in the 13C NMR at around d 50
(assigned to CH12a). The absence of a protoneproton coupling
between CH12a and CH13 was also instructive; both these CH
signals appeared as singlets as would be expected from the Karplus
equation for a dihedral torsional angle close to 90. Moreover, mass
spectrometry, elemental analysis and X-ray crystallography
(see Section 2.2) conﬁrmed the proposed structure of our com-
pounds. These observations indicate that the reaction did not
proceed to the ﬁnal dehydrated form of formula A; instead it pro-
gressed to the hydrated product represented by formula B (Scheme
1 and 2). Although the detailed mechanism of the reaction remains
to be fully clariﬁed, the formation of the unexpected hydrated
products could be explained as shown in Scheme 2, which involves
a sequence of condensation between tetronic acid (6) and theNH2N
N
O
O
O
CHO
R
E
R
2
5 6 7 (a-q)
7a, 8a R = 4-SCH3
7b, 8b R = 2-OCF3
7c, 8c R = 3-OCF3
7d, 8d R = 4-OCF3
7e, 8e R = 2-CF3
7f, 8f R = 3-CF3
7g, 8g R = 3-SF5
7h, 8h R = 3-CH3, 5-OCF3
7i, 8i R = 4-SCF3
7j, 8j R = 3
7k, 8k R =
7l, 8l R = 4
7m, 8m R
7n, 8n R =
7o, 8o R =
7p, 8p R =
7q, 8q R =
Scheme 1. Synthesis of the unexpected C3 hydroaromatic aldehydes (7a-q) to form the Knoevenagel adduct, fol-
lowed by Michael addition of the 1,10 phenanthroline amine then
cyclisation to afford the ﬁnal products (8a-q). In the literature there
is one similar hydrated product of azapodophyllotoxin analogues
reported in a microwave-assisted four-component reaction per-
formed in ammonia/water, but no assignment of the chirality of
ring C was mentioned [21].
2.2. Crystal structure analysis reveals the absolute conﬁguration of
the only two stereoisomers formed
In order to gain more insight into the chirality of the three
stereocentres (C1, C2 and C3 in Fig. 2) of our analogues, compound
8cwas selected for closer examination. Analysis of the X-ray crystal
structure of 8c established the relative conﬁguration of our prod-
ucts (Fig. 2). Only two enantiomers were observed; each of which
has a trans C1 C2 and cis C2 C3 lactone conﬁguration. The stereo-
selectivity in forming the cis g-lactone system can be attributed to
the higher thermodynamic stability compared to the strained trans
counterparts. This feature represents a particular metabolic
advantage, as epimerisation would be unlikely to occur in vivo.
2.3. Cell growth inhibitory activity
The anticancer activity of compounds (8a-q) was evaluated us-
ing the Oncotest monolayer assay in the human prostate cancer cell
line 22Rv1 and the human breast cancer cell line MCF-7, as an
outsourced service. Podophyllotoxin, etoposide and teniposide
were used as positive controls. Antitumour activity was assessed
after four days of treatment with the compounds using a propidium
iodide based monolayer assay [22]. Potency is expressed as abso-
lute IC50 values, calculated by non-linear regression analysis
following testing in triplicate. The seventeen inhibitors were tested
at 10 concentrations in half-log increments up to 100 mM in trip-
licate. The results summarised in Table 1 indicated that our com-
pounds have signiﬁcantly potent antiproliferative activity with IC50
values in the range of 0.11e7.25 mM, while the positive controls,
etoposide and teniposide exhibited IC50 values in the range ofH
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Scheme 2. A possible mechanism of the formation of the unexpected 4-azapodophyllotoxin products (8a-q) Formula B rather than Formula A.
A               B                   
Fig. 2. Crystal structure and absolute conﬁguration of the two enantiomers of compound 8c, (A) C1-S, C2-R and C3-R antipode, (B) C1-R, C2-S and C3-S antipode, (C) and (D) 2D
representation of (A) and (B) respectively.
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seventeen tested compounds showed pronounced activity with
IC50 values < 1 mM in both cell lines. These highly active inhibitors
showed sigmoidal concentration-effect curves with low bottom
plateaus indicating total cell kill at higher test concentration
(Fig. 3). Overall, 22Rv1 appeared to be slightly more sensitive than
MCF-7. The most active compound was shown to be 8e with IC50values of 0.11 mM (22Rv1) and 0.21 mM (MCF-7). Mean IC50
values < 0.5 mM were also detected for 8b-d, 8g, 8h, 8j, 8k and 8o,
and mean IC50 values between 0.5 mM and 1.0 mM for 8a, 8f, 8l, 8n
and 8q. Three further inhibitors (8i, 8m and 8p) exhibited mean
IC50 values < 10 mM.
While the structural requirements of ring E in podophyllotoxin
(PT) have not been extensively investigated because of the
Table 1
In vitro antiproliferative activity (mean IC50 in mM) of compounds (8a-q) across two
human cancer cell lines (MCF-7 and 22Rv1), following testing in triplicate.
Compound Ar MCF-7
IC50 (mM)
22Rv1
IC50 (mM)
8a 0.648 0.855
8b 0.288 0.165
8c 0.466 0.257
8d 0.424 0.239
8e 0.209 0.107
8f 0.825 0.510
8g 0.589 0.311
8h 0.475 0.242
8i 2.295 0.894
8j 0.643 0.380
8k 0.355 0.295
8l 0.901 0.719
8m 3.307 2.842
8n 0.857 0.590
8o 0.396 0.322
8p 7.250 4.002
8q 0.910 0.520
Table 1 (continued )
Compound Ar MCF-7
IC50 (mM)
22Rv1
IC50 (mM)
Etoposide
Teniposide
Podophyllotoxin
1.264
0.125
0.230
0.364
0.082
e
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data obtained in our series of compounds suggests that the
methoxy groups of ring E are not essential for the activity and the
best potency was observed with compounds having ortho substi-
tution of ring E; 2-triﬂuoromethyl 8e, 2-triﬂuoromethoxy 8b, and
2-methoxy-4-triﬂuoromethoxy 8o. Compounds with tri-
ﬂuoromethoxy substitution of ring E (8b-d, 8h, 8o) were among the
most active compounds, and this preference remains whether the
OCF3 is at the ortho (8b), meta (8c) or para (8d) position. Some
compounds like 8b-8e, 8g, 8h, 8k, 8o are more active than etopo-
side in both cell lines. Interestingly, ring E appeared to have toler-
ance towards a variety of ﬂuorinated substituents, for example 3-
pentaﬂuorosulfanyl (8g), 3, 5-bistriﬂuoromethyl (8j), 4-
pentaﬂuorosulfanyl (8n), and diﬂuoro-methylenedioxy analogues
(8q) have submicromolar activity. However, the myristicin-derived
substitution of ring E in compound (8p) exhibited some reduction
in the antiproliferative activity (IC50 7.3 mM and 4.0 mM in breast
MCF7 and prostate 22Rv1 cancer cell lines, respectively). Fig. 3
shows typical doseeresponse curves for two of the most active
compounds (8e and 8b) across the ten concentration values used in
the assay to calculate IC50 values.2.4. Docking studies reveals a structural basis for the anti-tubulin
activity
Computational docking simulations were performed to explore
the binding modes of the C3 hydroxy cis g-lactone APT analogues
(8a-q). All the synthesised compounds were docked into the
colchicine binding site of the human tubulin-podophyllotoxin
crystal structure (PDB ID: 1SA1) [23e25]. The in silico modelling
studies led to two major observations; ﬁrst, the stereochemistry at
carbon C1 (podophyllotoxin numbering system) is critical to the
ability of these compounds to ﬁt satisfactorily inside the tubulin
binding pocket. The C1-R-enantiomers of these compounds resul-
ted in better binding mode than those of the C1-S-enantiomers.
Interestingly, this is the same absolute conﬁguration of C1 of
podophyllotoxin. Second, our model predicts that the best ﬁtting
compounds are forming a particular stereochemical architecture
made of the C3 hydroxy group on one side of the molecule and the
cis lactone ring on the opposite side. This conﬁguration enables
these inhibitors to form a hydrogen bond bridge between the
carbonyl C]O group of the cis lactone ring and the side chain thiol
SH group of bCys241 on one side of the molecule, and between the
C3 hydroxy group OH and the backbone carbonyl C]O group of
bLys352 on the opposite side of the molecule. Fig. 4A depicts the
best docking ﬁt of compound 8e, C1-R-enantiomer. This novel
mode of interaction may explain why these compounds are able to
retain remarkable antitubulin activity in spite of having the noto-
riously unfavourable cis lactone system [26]. It is also worth
mentioning that according to our docking study this type of cross
linking interaction is only exhibited by C1-R-enantiomers, the C1-S
counterparts are not able to occupy the proper orientation required
for this binding mode. Instead, they display a “ﬂipped” conforma-
tion in the binding site, as shown in Fig. 4B vs. 4C, which depicts
Fig. 3. Cell viability dose response relationship of 8e (A) and 8b (B) in the Oncotest monolayer assay showing sigmoidal concentration-effect curves with low bottom plateaus
indicating total cell kill at higher test concentration. The y-axis is representative of cell viability, as measured via the propidium iodide endpoint assay.
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orientation (C1-S-enantiomer Fig. 4C). Interestingly, our system
predicts a hydrogen bond formation between the OCF3 moiety in
compound 8c and the backbone NH group of bLys352 (Fig. 4B).
Notably, most ring E substitution patterns docked well in the
binding site and showed little difference in the docking scores. This
could be attributed to the predominance of the hydrophobic in-
teractions in the site occupied by this ring, which allow for pro-
miscuous substituents on the E ring. This observation is in
accordance with the slight ﬂuctuation in the potencies of most of
these compounds in the cell viability tests (Table 1). In the case of
compounds 8p and 8q, the relatively bulky structure of ring E
would clash with the protein and prevent them from occupying the
above mentioned binding mode which features the simultaneous
interaction with bCys241 and bLys352, instead they nicely overlay
with podophyllotoxin where the tricyclic 1,10 phenanthroline ring
maps well with ring E of podophyllotoxin while the methyl-
enedioxy ring in both compounds overlap with rings A and B of the
natural product Fig. 4D and E. Also, the relative reduction in the
activity of compound 8p could be attributed to the size of the
additional methoxy group in ring E,which is likely to cause clashes
within the protein binding site (Fig. 4D).2.5. Analogues 8e and 8b induce disruption of the microtubule
cytoskeleton in MCF-7 breast cancer cells
In order to investigate the microtubule-destabilising ability of
these analogues, experiments were conducted to determine their
effects on the subcellular organisation of microtubules in vitro [27].
For this we studied the most active compounds 8e and 8b using
immunoﬂuorescence assays and confocal microscopy. These ana-
lyses of a-tubulin in treated versus control MCF-7 cells (Fig. 5)
revealed that our 4-azapodophyllotoxin analogues possessed
microtubule deregulating activity with evidence of enhanced
speciﬁcity for dividing cells compared with podophyllotoxin.
Diluent control treated cells in interphase exhibited typical nest-
like microtubule networks comprised of long, regularly arranged
ﬁlaments (Fig. 5): 0.01% DMSO (top row). The nuclei of control
interphase cells were relatively monomorphic. Dividing control
cells demonstrated classic hallmarks of different phases of mitosis
e.g. congressed chromosomes, and the formation of symmetrical,
bipolar spindles (Fig. 5): 0.01% DMSO (bottom row). All podo-
phyllotoxin treated cells showed a dramatic disruption of the
tubulin cytoskeleton: there was a signiﬁcant loss of ﬁlamentousstructures and evidence of nuclear atypia and pyknosis. Analogue
treated cells in interphase featured shorter microtubule ﬁlaments
and slightly more disordered microtubule networks than control
cells. However, compared with podophyllotoxin, 8e and 8b induced
more subtle changes in the tubulin ﬁlaments and their organisa-
tion. Deregulation of the tubulin cytoskeleton by our analogues was
most striking in dividing cells, which displayed a variety of
microtubule and nuclear abnormalities. Compound 8e and 8b-
induced defects included aberrations of spindle morphology and
polarity, nuclear atypia (pleomorphism, pyknosis) and uncon-
gressed/misaligned chromosomes. Impairment of cytokinesis was
demonstrated by an accumulation of binucleate cells joined by
intracellular bridges (red arrowheads in Fig. 5).2.6. Analogues 8e and 8b do not impair microtubule polymerisation
in MCF-7 breast cancer cells
Cold depolymerisation of the tubulin cytoskeleton in vitro,
including in MCF-7 cells, can be achieved by relatively short in-
cubations at 4 C [27-29]. To test the ability of the compounds to
impair microtubule polymerisation, following depolymerisation,
two variations of a tubulin re-polymerisation assay were per-
formed. In the ﬁrst, MCF-7 cells were pre-treated for 6 h with
250 nM of the compounds before being incubated on ice for 30 min
then rewarmed to 37 C for a further 30 min. In the second varia-
tion, cells were ﬁrst incubated on ice then rewarmed to 37 C in the
presence of the compounds (250 nM, 30 min total treatment time).
Samples of cells were ﬁxed post-cold depolymerisation and post-
warm repolymerisation. In both variations, immunoﬂuorescence
for a-tubulin was performed and cells were imaged by confocal
microscopy (Fig. 6 and 7). In control and treated cells, incubation on
ice for 30 min led to total loss of ﬁlamentous tubulin and the pro-
tein was diffusely scattered throughout the cytoplasm. The com-
pounds therefore did not inhibit depolymerisation of the
microtubules. Upon increasing the temperature to 37 C for 30 min
there was clear repolymerisation of the microtubule network. Both
assay variations demonstrated that the podophyllotoxin positive
controls signiﬁcantly impaired the repolymerisation of tubulin
following cold depolymerisation (Figs. 6 and 7). In the cells pre-
treated for 6 h with 8e or 8b (Fig. 6), the microtubule cytoskel-
eton was still able to reform but mitotic defects and shorter ﬁla-
ments, as seen in Fig. 5, were evident in interphase cells. After a
30 min rewarming incubation in the presence of these analogues
the microtubule cytoskeleton was able to reform with negligible
Fig. 4. The predicted binding modes of compound 8e, C1-R-enantiomer (A); and compound 8c; C1-R-enantiomer (B), both showing the cross linking hydrogen bonds formed
between Cys 241 and Lys 352 amino acids (blue dashed lines) compared to the ﬂipped orientation of 8c, C1eS-enantiomer (C). The predicted binding modes of compounds 8p; C1-
R-enantiomer (D) and 8q; C1-R-enantiomer (E), both overlaid with the co-crystallised podophyllotoxin molecule (in white). (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 5. Microtubule deregulation in MCF-7 cells induced by podophyllotoxin and analogues 8e and 8b. MCF-7 cells were treated for 6 h with 250 nM of the compounds (or the
equivalent concentration of DMSO diluent control) as indicated. Cells were ﬁxed with 100% methanol at 20 C for 10 min and subjected to immunoﬂuorescence analysis for a-
tubulin (green channel). Nuclei were counterstained with Hoechst (blue channel). Cells were imaged by confocal microscopy and representative images from three independent
experiments are shown. Cell defects are indicated as follows: pyknotic nucleus (red asterisk), intracellular bridge forming a binucleate cell (red arrowhead), aberrant spindle
morphology (purple arrowhead), asymmetric spindle formation (green arrowhead), loss of spindle polarity (blue arrowhead). (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
S. Kandil et al. / European Journal of Medicinal Chemistry 110 (2016) 311e325318defects (Fig. 7).
The anti-cancer activity of tubulin binding drugs such as pacli-
taxel and vincristine is a consequence of their ability to deregulate
spindle microtubule dynamics; inducing mitotic arrest and
apoptosis [30]. The mitotic defects generated in MCF-7 breast
cancer cells by 8e and 8b treatment (Fig. 5), and the more modest
effects on tubulin morphology and polymerisation in interphase
cells (Figs. 5e7), suggest a degree of selectivity for dividing cells.
Such selectivity is a key feature of many successful anticancer
compounds and taken together with the viability data shown in
Table 1, the results suggest that these analogues have chemother-
apeutic potential through the suppression of spindle microtubule
dynamics.3. Conclusions
A series of 4-azapodophyllotoxin derivatives were synthesised
using a multicomponent reaction (MCR) of 1,10 phenanthroline
amine (5), tetronic acid (6) and various ﬂuorinated and non-
ﬂuorinated aromatic aldehydes (7a-q). To our surprise we ob-
tained the unexpected C3 hydroxy cis g-lactone derivatives (8a-q)
and proved unequivocally that the previously reported structure is
not accurate. Moreover, the reaction proceeded in favour of the
formation of only two thermodynamically stable cis g lactone en-
antiomers as conﬁrmed by the X-ray crystal structure studies. This
ﬁnding is of particular interest in terms of the biochemical mech-
anism by which podophyllotoxin compounds are metabolised
where the release of the highly strained trans g-lactone system inpodophyllotoxin analogues into the more stable C3 hydroxy cis
lactonemotif and yet retaining a signiﬁcantly potent activity should
allow for improved pharmacokinetic properties. These compounds
were evaluated against two human cancer lines MCF-7 and 22Rv1.
Fourteen out of the seventeen tested compounds exhibited sub-
micromolar activity with IC50 values in the range of
0.11e0.91 mM. Confocal microscopy studies conﬁrmed that ana-
logues 8b and 8e had signiﬁcant effects on microtubular
morphology that was different to PT, potentially with greater
selectivity for dividing cells. Molecular modelling simulations
predicted a theoretical basis for our ﬁndings.
Overall, this study provides, for the ﬁrst time, the cis selective C3
hydroxy g-lactone conﬁguration into podophyllotoxin-mimetic li-
braries and lays a foundation for the development of alternative
tubulin targeting therapies capable of combating cancer.4. Experimental section
4.1. Chemistry
All chemicals were purchased from SigmaeAldrich or Alfa Aesar
and were used without further puriﬁcation. Thin Layer Chroma-
tography (TLC): precoated aluminium backed plates (60 F254,
0.2 mm thickness, Merck) were visualized under both short and
long wave UV light (254 and 366 nm). Flash column chromatog-
raphy was carried out using silica gel supplied by Fisher (60A,
35e70 mm). Analytical High Performance Liquid Chromatography
(HPLC) analysis was performed using either a ThermoScientiﬁc or a
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19F NMR (470 MHz) spectra were recorded on a Bruker Avance
500MHz spectrometer at 25 C. Chemical shifts (d) are expressed in
parts per million (ppm) and coupling constants (J) are given in
hertz. The following abbreviations are used in the assignment of
NMR signals: s (singlet), bs (broad singlet), d (doublet), t (triplet), q
(quartet), qn (quintet), m (multiplet), dd (doublet of doublet), dt
(doublet of triplet), td (triple doublet), dq (double quartet), m
(multiplet), dm (doublemultiplet). Mass spectrometry was run on a
Bruker Micromass system in electrospray ionisation mode. Accu-
rate mass spectrometry was performed at the EPSRC UK National
Mass Spectrometry facility at Swansea University. Elemental anal-
ysis (% C, H, N) was run at Medac Ltd. (Chobham, Surrey, U.K.) as an
external service.
4.1.1. General synthesis of 4-aza-3-hydroxy-1,2-trans-2,3-cis-
lactone podophyllotoxin derivatives
These derivatives were synthesised by following a previously
reported method [13]. An equimolar mixture of commercially
available tetronic acid, 1,10 phenanthroline amine and the corre-
sponding aromatic aldehyde was dissolved in ethanol. The reaction
mixture was heated under reﬂux for 2e6 h. After cooling, the sol-
vent was removed in vacuo and the product was recrystallised from
methanol to afford the desired compounds in pure form.
4.1.1.1. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 9a-hydroxy-13-(4-
(methylthio)phenyl)-9a,10,12a,13-tetrahydrofuro[3,4-b]pyrido[3,2-f]
[1,10]phenanthrolin-12(9H)-one (8a). Yield: 76 1H NMR (500 MHz,
DMSO-d6) d 9.11 (dd, J ¼ 1.5, 4.5 Hz, 1H, ArH), 8.91 (dd, J ¼ 1.5,
8.5 Hz,1H, ArH), 8.72 (d, J¼ 1.5, 4 Hz,1H, ArH), 7.93 (dd, J¼ 1.5, 9 Hz,
1H, ArH), 7.85 (dd, J ¼ 4.5, 8.5 Hz, 1H, ArH), 7.51 (s, 1H, NH-9), 7.48
(dd, J ¼ 4, 8.5 Hz, 1H, ArH), 7.22 (d, J ¼ 8.5 Hz, 2H, ArH), 7.11 (d,
J ¼ 8.5 Hz, 2H, ArH), 6.05 (s, 1H, OH), 4.98 (s, 1H, CH-13), 4.57 (d,
J¼ 8.5 Hz,1H, CH-10), 4.21 (d, J¼ 8.5 Hz,1H, CH-10), 3.55 (s,1H, CH-
12a), 2.41 (s, 3H, CH3). 13C NMR (125 MHz, DMSO-d6) d 174.59 (C]
O), 149.59 (ArCH), 145.75 (ArC), 145.18 (ArCH), 141.14 (ArC), 139.10
(ArC), 135.79 (ArC), 135.40 (ArC), 130.01 (ArCH), 129.87 (ArCH),
129.05 (ArCH-30,5’), 128.43 (ArC), 125.77 (ArCH), 123.27 (ArCH),
122.59 (ArCH), 120.56 (ArC), 104.12 (ArC), 81.89 (COH-9a), 74.49
(CH2-10), 50.09 (CH-12a), 35.94 (CH-13), 14.56 (SCH3). HRMS calcd
for C24H19N3O3S (M þ H)þ, 430.1220; found, 430.1217.
4.1.1.2. (9aS, 12aS, 13S) and (9aR, 12aR, 13R) 9a-hydroxy-13-(2-(tri-
ﬂuoromethoxy)phenyl)-9a,10,12a,13-tetrahydrofuro[3,4-b]pyrido[3,2-
f][1,10]phenanthrolin-12(9H)-one (8b). Yield: 72% 1H NMR
(500 MHz, DMSO-d6) d 9.18 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 8.98 (dd,
J ¼ 1, 8.5 Hz, 1H, ArH), 8.78 (d, J ¼ 1.5, 4.5 Hz, 1H, ArH), 7.91 (dd,
J ¼ 4, 8.5 Hz, 1H, ArH), 7.67 (dd, J ¼ 1.5, 8.5 Hz, 1H, ArH), 7.63 (s, 1H,
NH-9), 7.57e7.51 (m, 2H, ArH), 7.40 (ddd, J ¼ 2, 7.5, 9 Hz, 1H, ArH),
7.13 (td, J ¼ 1, 8 Hz, 1H, ArH), 7.02 (dd, J ¼ 1, 8 Hz, 1H, ArH), 6.19 (s,
1H, OH-9a), 5.29 (s, 1H, CH-13), 4.65 (d, J ¼ 8.5 Hz, 1H, CH-10), 4.33
(d, J ¼ 8.5 Hz, 1H, CH-10), 3.50 (s, 1H, CH-12a); 19F NMR (DMSO-d6)
d 55.36; 13C NMR (125 MHz, DMSO-d6) d 173.97 (C]O), 149.86
(ArCH), 146.10 (ArC), 145.90 (ArC), 145.35 (ArCH), 141.33 (ArC),
136.30 (ArC), 133.81 (ArC), 131.11 (ArCH), 130.07 (ArCH), 128.78
(ArCH), 128.42 (ArCH), 128.08 (ArC), 127.03 (ArCH), 123.42 (ArCH),
122.70 (ArCH), 120.93 (q, 1JC-F ¼ 256 Hz, CF3), 120.55 (ArC), 120.18
(ArCH), 102.43 (ArC), 81.65 (COH-9a), 74.54 (CH2-10), 48.35 (CH-
12a), 30.37 (CH-13). HRMS calcd for C24H16F3N3O4 (M þ H)þ,
468.1166; found, 468.1158.
4.1.1.3. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 9a-hydroxy-13-(3-(tri-
ﬂuoromethoxy)phenyl)-9a,10,12a,13-tetrahydrofuro[3,4-b]pyrido[3,2-
f][1,10]phenanthrolin-12(9H)-one (8c). Yield: 74% 1H NMR
(500 MHz, DMSO-d6) d 9.12 (dd, J ¼ 1.5, 4.5 Hz, 1H, ArH), 8.93 (dd,J ¼ 1.5, 8.5 Hz, 1H, ArH), 8.72 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 7.94 (dd,
J¼ 1.5, 8.5 Hz,1H, ArH), 7.86 (dd, J¼ 4.5, 8.5 Hz,1H, ArH), 7.56 (s,1H,
NH-9), 7.48 (dd, J ¼ 4.5, 8.5 Hz, 1H, ArH), 7.40e7.33 (m, 2H, ArH),
7.25 (s, 1H, ArH), 7.19e7.14 (m, 1H, ArH), 6.16 (s, 1H, OH-9a), 5.10 (s,
1H, CH-13), 4.58 (d, J ¼ 8.5 Hz, 1H, CH-10), 4.23 (d, J ¼ 8.5 Hz, 1H,
CH-10), 3.63 (s, 1H, CH-12a); 19F NMR (DMSO-d6) d 56.62; 13C
NMR (125 MHz, DMSO-d6) d 174.31 (C]O), 149.75 (ArCH), 148.23
(ArC), 145.85 (ArC), 145.32 (ArCH), 145.21 (ArC), 141.17 (ArC), 135.59
(ArC), 130.08 (ArCH), 130.03 (ArCH), 129.70 (ArCH), 128.28 (ArC),
127.67 (ArCH), 123.31 (ArCH), 122.64 (ArCH), 121.14 (ArCH), 120.98
(q, 1JC-F ¼ 234 Hz, CF3), 120.54 (ArC), 118.79 (ArCH), 103.51 (ArC),
81.84 (COH-9a), 74.45 (CH2-10), 49.81 (CH-12a), 36.04 (CH-13).
HRMS calcd for C24H16F3N3O4 (Mþ H)þ, 468.1166; found, 468.1160.
4.1.1.4. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 9a-hydroxy-13-(4-(tri-
ﬂuoromethoxy)phenyl)-9a,10,12a,13-tetrahydrofuro[3,4-b]pyrido[3,2-
f][1,10]phenanthrolin-12(9H)-one (8d). Yield: 70% 1H NMR
(500 MHz, DMSO-d6) d 9.12 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 8.92 (dd,
J ¼ 1.5, 8.5 Hz, 1H, ArH), 8.73 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 7.93 (dd,
J ¼ 1.5, 8.5 Hz, 1H, ArH), 7.85 (dd, J ¼ 4, 8.5 Hz, 1H, ArH), 7.52 (s, 1H,
NH-9), 7.48 (dd, J ¼ 4, 8 Hz, 1H, ArH), 7.41 (d, J ¼ 8.5, 2H, ArH), 7.21
(d, J ¼ 8.5, 2H, ArH), 6.08 (s, 1H, OH-9a), 5.09 (s, 1H, CH-13), 4.59 (d,
J¼ 8.5 Hz,1H, CH-10), 4.23 (d, J¼ 8.5 Hz,1H, CH-10), 3.62 (s,1H, CH-
12a); 19F NMR (DMSO-d6) d 56.75; 13C NMR (125 MHz, DMSO-d6)
d 174.36 (C]O), 149.69 (ArCH), 146.81 (ArC), 145.87 (ArC), 145.28
(ArCH), 141.65 (ArC), 141.25 (ArC), 135.51 (ArC), 130.36 (ArCH),
130.02 (ArCH), 129.68 (ArCH), 128.32 (ArC), 123.32 (ArCH), 122.59
(ArCH),120.67 (ArCH),120.56 (ArC), 120.52 (q, 1JC-F¼ 253.9 Hz, CF3),
103.81 (ArC), 81.92 (COH-9a), 74.55 (CH2-10), 49.94 (CH-12a), 35.76
(CH-13). HRMS calcd for C24H16F3N3O4 (M þ H)þ, 468.1166; found,
468.1158.
4.1.1.5. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 9a-hydroxy-13-(2-(tri-
ﬂuoromethyl) phenyl)-9a,10,12a,13-tetrahydrofuro[3,4-b]pyrido[3,2-
f][1,10]phenanthrolin-12(9H)-one (8e). Yield: 68% 1H NMR
(500 MHz, DMSO-d6) d 9.17 (dd, J ¼ 1.5, 4.5 Hz, 1H, ArH), 9.00 (dd,
J ¼ 1.5, 8.5 Hz, 1H, ArH), 8.75 (dd, J ¼ 1.5, 4.5 Hz, 1H, ArH), 7.91 (dd,
J ¼ 4.5, 8.5 Hz, 1H, ArH), 7.89 (dd, J ¼ 1, 8 Hz, 1H, ArH), 7.78 (dd,
J¼ 1.5, 5 Hz,1H, ArH), 7.67 (s, 1H, NH-9), 7.52 (dd, J¼ 4.5, 8.5 Hz,1H,
ArH), 7.46 (t, J¼ 7.5 Hz,1H, ArH), 7.39 (t, J¼ 7.5 Hz,1H, ArH), 7.28 (d,
J ¼ 7.5 Hz, 1H, ArH), 6.19 (s, 1H, OH-9a), 5.31 (s, 1H, CH-13), 4.65 (d,
J¼ 8.5 Hz,1H, CH-10), 4.30 (d, J¼ 8.5 Hz,1H, CH-10), 3.53 (s,1H, CH-
12a); 19F NMR (DMSO-d6) d 57.66; 13C NMR (125 MHz, DMSO-d6)
d 173.79 (C]O), 149.91 (ArCH), 145.91 (ArC), 145.32 (ArCH), 141.40
(ArC), 140.51 (ArC), 136.45 (ArC), 132.30 (ArCH), 131.62 (ArCH),
130.15 (ArCH), 128.43 (ArCH), 128.11 (ArC), 127.51 (ArCH), 126.32 (q,
3JC-F ¼ 5.9 Hz, ArCH), 126.54 (q, 2JC-F ¼ 29 Hz, ArC), 125.45 (q, 1JC-
F ¼ 272.5 Hz, CF3), 123.37 (ArCH), 122.75 (ArCH), 120.55 (ArC),
103.49 (ArC), 81.61 (COH-9a), 74.41 (CH2-10), 49.12 (CH-12a), 33.25
(CH-13). HRMS calcd for C24H16F3N3O3 (M þ H)þ, 452.1217; found,
452.1211.
4.1.1.6. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 9a-hydroxy-13-(3-(tri-
ﬂuoromethyl) phenyl)-9a,10,12a,13-tetrahydrofuro[3,4-b]pyrido[3,2-
f][1,10]phenanthrolin-12(9H)-one (8f). Yield: 71% 1H NMR
(500 MHz, DMSO-d6) d 9.13 (dd, J ¼ 1, 4 Hz, 1H, ArH), 8.93 (dd, J ¼ 1,
8.5 Hz, 1H, ArH), 8.73 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 7.94 (dd, J ¼ 1.5,
9 Hz, 1H, ArH), 7.86 (dd, J ¼ 4.5, 8.5 Hz, 1H, ArH), 7.73 (s, 1H, NH-9),
7.57e7.50 (m, 3H, ArH), 7.48 (dd, J ¼ 4, 8.5 Hz, 1H, ArH), 7.44 (t,
J ¼ 8 Hz, 1H, ArH), 6.13 (s, 1H, OH-9a), 5.16 (s, 1H, CH-13), 4.59 (d,
J ¼ 8.5 Hz, 1H, CH-10), 4.23 (d, J ¼ 9 Hz, 1H, CH-10), 3.65 (s, 1H, CH-
12a); 19F NMR (DMSO-d6) d 60.82; 13C NMR (125 MHz, DMSO-d6)
d 174.22 (C]O), 149.75 (ArCH), 145.88 (ArC), 145.33 (ArCH), 143.66
(ArC), 141.21 (ArC), 135.69 (ArC), 132.69 (ArCH), 130.08 (ArCH),
129.69 (ArCH), 129.15 (ArCH), 129.42 (q, 2JC-F ¼ 31.6 Hz, ArC), 128.27
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CF3), 123.34 (ArCH), 123.29 (q, 3JC-F ¼ 3.9 Hz, ArCH), 122.63 (ArCH),
120.55 (ArC), 103.43 (ArC), 81.89 (COH-9a), 74.52 (CH2-10), 49.90
(CH-12a), 36.09 (CH-13). HRMS calcd for C24H16F3N3O3 (M þ H)þ,
452.1217; found, 452.1211.
4.1.1.7. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 9a-hydroxy-13-(3-
(pentaﬂuorosulfanyl) phenyl)-9a,10,12a,13-tetrahydrofuro[3,4-b]pyr-
ido[3,2-f][1,10]phenanthrolin-12(9H)-one (8g). Yield: 78% 1H NMR
(500 MHz, DMSO-d6) d 9.13 (dd, J ¼ 1.5, 4.5 Hz, 1H, ArH), 8.93 (dd,
J ¼ 1.5, 8.5 Hz, 1H, ArH), 8.73 (dd, J ¼ 1.5, 4.5 Hz, 1H, ArH), 7.97 (dd,
J ¼ 1.5, 8.5 Hz, 1H, ArH), 7.93 (t, J ¼ 1.5 Hz, 1H, ArH), 7.68 (dd, J ¼ 4,
8.5 Hz, 1H, ArH), 7.70 (ddd, J ¼ 1, 2, 8.5 Hz, 1H, ArH), 7.55 (s, 1H, NH-
9), 7.54e7.47 (m, 2H, ArH), 7.43 (t, J¼ 8 Hz,1H, ArH), 6.18 (s, 1H, OH-
9a), 5.19 (s, 1H, CH-13), 4.59 (d, J ¼ 8.5 Hz, 1H, CH-10), 4.24 (d,
J ¼ 8.5 Hz, 1H, CH-10), 3.66 (s, 1H, CH-12a); 19F NMR (DMSO-d6)
d 87.75 (qn, J ¼ 148.7 Hz, 1F), 64.12 (d, J ¼ 150.6 Hz, 4F); 13C NMR
(125 MHz, DMSO-d6) d 174.08 (C]O), 149.80 (ArCH), 145.91 (ArC),
145.37 (ArCH), 144.07 (ArC), 141.22 (ArC), 135.73 (ArC), 132.62
(ArCH), 130.10 (ArCH), 129.62 (ArCH), 129.14 (ArCH), 128.18 (ArC),
126.93 (ArC), 125.80 (m, ArCH), 123.95 (m, ArCH), 123.37 (ArCH),
122.65 (ArCH), 120.53 (ArC), 103.34 (ArC), 81.87 (COH-9a), 74.53
(CH2-10), 49.77 (CH-12a), 36.16 (CH-13). MS (ESI): 510.1 [MþH]þ.
C23H16F5N3O3S calcd (C, 54.23; H, 3.17; N, 8.24); found (C, 54.39; H,
3.24; N, 8.47).
4.1.1.8. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 9a-hydroxy-13-(3-
methyl-5-triﬂuoromethoxyphenyl)-9a,10,12a,13-tetrahydrofuro[3,4-
b]pyrido[3,2-f][1,10] phenanthrolin-12(9H)-one (8h). Yield: 73% 1H
NMR (500 MHz, DMSO-d6) d 9.12 (dd, J¼ 1, 4 Hz, 1H, ArH), 8.92 (dd,
J ¼ 1.5, 9 Hz, 1H, ArH), 8.73 (ddd, J ¼ 0.5, 1.5, 4.5 Hz, 1H, ArH), 7.92
(dd, J ¼ 1.5, 8.5 Hz, 1H, ArH), 7.86 (dd, J ¼ 4, 8.5 Hz, 1H, ArH),
7.52e7.47 (m, 2H, ArH), 7.25 (s, 1H, NH-9), 6.98 (s, 1H, ArH), 7.95 (s,
1H, ArH), 6.10 (s, 1H, OH-9a), 5.03 (s, 1H, CH-13), 4.58 (d, J ¼ 8 Hz,
1H, CH-10), 4.23 (d, J ¼ 8 Hz, 1H, CH-10), 3.60 (s, 1H, CH-12a), 2.27
(s, 3H, CH3); 19F NMR (DMSO-d6) d 56.51; 13C NMR (125 MHz,
DMSO-d6) d 174.29 (C]O), 149.71 (ArCH), 148.23 (q, 3JC-F ¼ 1.9 Hz,
ArC), 145.87 (ArC), 145.30 (ArCH), 144.98 (ArC), 141.18 (ArC), 139.99
(ArC), 135.58 (ArC), 130.09 (ArCH), 129.71 (ArCH), 128.35 (ArC),
128.16 (ArCH), 124.27 (q, 1JC-F ¼ 272.5 Hz, CF3), 123.29 (ArCH),
122.60 (ArCH), 120.56 (ArC), 119.27 (ArCH), 118.15 (ArCH), 103.50
(ArC), 81.83 (COH-9a), 74.46 (CH2-10), 49.95 (CH-12a), 36.16 (CH-
13), 20.82 (ArCH3). MS (ESI): 482.1 [MþH]þ, 504.1 [MþNa]þ.
C25H18F3N3O4 calcd (C, 62.37; H, 3.77; N, 8.72); found (C, 62.32; H,
3.75; N, 8.70).
4.1.1.9. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 9a-hydroxy-13-(4-
((triﬂuoromethyl)thio)phenyl)-9a,10,12a,13-tetrahydrofuro[3,4-b]
pyrido [3,2-f][1,10]phenanthrolin-12(9H)-one (8i). Yield: 79% 1H
NMR (500 MHz, DMSO-d6) d 9.12 (dd, J ¼ 1.5, 4.5 Hz, 1H, ArH), 8.92
(dd, J ¼ 1.5, 8.5 Hz, 1H, ArH), 8.72 (d, J ¼ 1.5, 4.5 Hz, 1H, ArH), 7.92
(dd, J ¼ 1.5, 8.5 Hz, 1H, ArH), 7.85 (dd, J ¼ 4.5, 8.5 Hz, 1H, ArH), 7.58
(d, J ¼ 8.5 Hz, 2H, ArH), 7.54 (s, 1H, NH-9), 7.47 (dd, J ¼ 4.5, 8.5 Hz,
1H, ArH), 7.45 (d, J¼ 8.5 Hz, 2H, ArH), 6.11 (s, 1H, OH-9a), 5.11 (s, 1H,
CH-13), 4.59 (d, J ¼ 8.5 Hz, 1H, CH-10), 4.25 (d, J ¼ 8.5 Hz, 1H, CH-
10), 3.65 (s, 1H, CH-12a). 19F NMR (DMSO-d6) d 42.03, 13C NMR
(125 MHz, DMSO-d6) d 174.28 (C]O), 149.72 (ArCH), 146.16 (ArC),
145.88 (ArC), 145.30 (ArCH), 141.23 (ArC), 136.01 (ArCH), 135.63Fig. 6. Microtubule repolymerisation in cold-depolymerised MCF-7 cells following 6 h pre-tr
with 250 nM of the compounds (or the equivalent concentration of DMSO diluent control) as
methanol at 20 C for 10 min (top rows) while some were rewarmed at 37 C for 30 min p
tubulin (green channel). Nuclei were counterstained with Hoechst (blue channel). Cells we
experiments are shown. (For interpretation of the references to colour in this ﬁgure legend(ArC), 130.20 (ArCH),130.05 (ArCH), 129.60 (q, 1JC-F ¼ 306.3 Hz,
SCF3), 129.62 (ArCH),128.30 (ArC), 123.32 (ArCH), 122.61 (ArCH),
120.67 (q, 3JC-F ¼ 1.8 Hz, ArC), 120.56 (ArC), 103.46 (ArC), 81.90
(COH-9a), 74.54 (CH2-10), 49.81 (CH-12a), 36.11 (CH-13). MS (ESI):
484.1 [MþH]þ, 506.1 [MþNa]þ. C24H16F3N3O3S calcd (C, 59.62; H,
3.34; N, 8.69); found (C, 59.29; H, 3.35; N, 8.55).
4.1.1.10 . (9aS , 12aR, 13R) and (9aR, 12aS , 13S) 13-(3 ,5-
bis(triﬂuoromethyl)phenyl)-9a-hydroxy-9a,10,12a,13-tetrahydrofuro
[3,4-b]pyrido[3,2-f][1,10] phenanthrolin-12(9H)-one (8j). Yield: 74%
1H NMR (500 MHz, DMSO-d6) d 9.14 (dd, J ¼ 1, 4 Hz, 1H, ArH), 8.95
(dd, J ¼ 1.5, 9 Hz, 1H, ArH), 8.74 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 8.00 (dd,
J ¼ 1.5, 8.5 Hz, 1H, ArH), 7.98 (s, 2H, ArH), 7.94 (s, 1H, ArH), 7.88 (dd,
J ¼ 4, 8.5 Hz, 1H, ArH), 7.63 (s, 1H, NH-9), 7.50 (dd, J ¼ 4, 8.5 Hz, 1H,
ArH), 6.31 (s, 1H, OH-9a), 5.33 (s, 1H, CH-13), 4.60 (d, J ¼ 8.5 Hz, 1H,
CH-10), 4.23 (d, J¼ 8.5 Hz,1H, CH-10), 3.75 (s, 1H, CH-12a); 19F NMR
(DMSO-d6) d 61.15; 13C NMR (125 MHz, DMSO-d6) d 173.85 (C]
O), 149.98 (ArCH), 145.93 (ArC), 145.51 (ArCH), 141.16 (ArC), 135.95
(ArC), 130.19 (ArCH), 130.02 (ArC), 129.76 (ArC), 129.65 (ArCH),
129.50 (m, ArCH), 128.06 (ArC), 123.51 (ArCH), 122.74 (ArCH),
123.77 (q, 1JC-F ¼ 271.4 Hz, CF3), 120.64 (m, ArCH), 120.49 (ArC),
102.61 (ArC), 81.81 (COH-9a), 74.45 (CH2-10), 49.52 (CH-12a), 35.66
(CH-13). MS (ESI): 520.1 [MþH]þ, 542.1 [MþNa]þ. C25H15F6N3O3
calcd (C, 57.81; H, 2.91; N, 8.09); found (C, 57.60; H, 2.96; N, 8.21).
4.1.1.11. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 13-(4-ethoxy-3-(tri-
ﬂuoromethyl) phenyl)-9a-hydroxy-9a,10,12a,13-tetrahydrofuro[3,4-b]
pyrido[3,2-f][1,10] phenanthrolin-12(9H)-one (8k). Yield: 73% 1H
NMR (500 MHz, DMSO-d6) d 9.12 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 8.92
(dd, J ¼ 1.5, 8.5 Hz, 1H, ArH), 8.73 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 7.96
(dd, J ¼ 1.5, 8.5 Hz, 1H, ArH), 7.85 (dd, J ¼ 4.5, 8.5 Hz, 1H, ArH), 7.60
(d, J¼ 2.5 Hz,1H, ArH), 7.54e7.46 (m, 2H, NH-9, ArH), 7.39 (dd, J¼ 2,
9 Hz, 1H, ArH), 7.05 (d, J ¼ 8.5, 1H, ArH), 6.10 (s, 1H, OH-9a), 5.06 (s,
1H, CH-13), 4.58 (d, J ¼ 8 Hz, 1H, CH-10), 4.22 (d, J ¼ 8 Hz, 1H, CH-
10), 4.11e4.04 (m, 2H, CH3CH2), 3.60 (s,1H, CH-12a),1.29 (t, J¼ 7 Hz,
3H, CH3CH2); 19F NMR (DMSO-d6) d 60.64; 13C NMR (125 MHz,
DMSO-d6) d 174.32 (C]O), 154.90 (ArC), 149.67 (ArCH), 145.85
(ArC), 145.29 (ArCH), 141.20 (ArC), 135.48 (ArC), 133.98 (ArCH),
133.96 (ArC), 130.04 (ArCH), 129.80 (ArCH), 128.33 (ArC), 126.70 (q,
3JC-F ¼ 5.1 Hz, ArCH), 123.83 (q, 1JC-F ¼ 270.6 Hz, CF3), 123.33 (ArCH),
122.59 (ArCH), 120.55 (ArC), 116.77 (q, 2JC-F ¼ 29 Hz, ArC), 113.31
(ArCH), 103.87 (ArC), 81.91 (COH-9a), 74.55 (CH2-10), 64.39
(CH2CH3), 50.00 (CH-12a), 35.32 (CH-13), 14.39 (CH2CH3). MS (ESI):
496.1 [MþH]þ, 518.1 [MþNa]þ. C26H20F3N3O4 calcd (C, 63.03; H,
4.07; N, 8.48); found (C, 62.68; H, 3.98; N, 8.55).
4.1.1.12. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 13-(4-(diﬂuor-
omethoxy)phenyl)-9a-hydroxy-9a,10,12a,13-tetrahydrofuro[3,4-b]
pyrido[3,2-f][1,10]phenanthrolin-12(9H)-one (8l). Yield: 65% 1H
NMR (500 MHz, DMSO-d6) d 9.11 (dd, J ¼ 1.5, 4.5 Hz, 1H, ArH), 8.91
(dd, J ¼ 1.5, 9 Hz, 1H, ArH), 8.72 (dd, J ¼ 1.5, 4.5 Hz, 1H, ArH), 7.93
(dd, J ¼ 1.5, 9 Hz, 1H, ArH), 7.85 (dd, J ¼ 4.5, 8.5 Hz, 1H, ArH), 7.50 (s,
1H, NH-9), 7.48 (dd, J ¼ 4.5, 8.5 Hz, 1H, ArH), 7.34 (d, J ¼ 8.5, 2H,
ArH), 7.16 (t, 2JH-F¼ 74.5,1H, ArCF2H), 7.03 (d, J¼ 9, 2H, ArH), 6.06 (s,
1H, OH-9a), 5.04 (s, 1H, CH-13), 4.58 (d, J ¼ 8.5 Hz, 1H, CH-10), 4.23
(d, J ¼ 8.5 Hz, 1H, CH-10), 3.57 (s, 1H, CH-12a); 19F NMR (DMSO-d6)
d 81.85; 13C NMR (125 MHz, DMSO-d6) d 174.47 (C]O), 149.62
(ArCH), 149.35 (ArC), 145.84 (ArC), 145.23 (ArCH), 141.24 (ArC),eatment with podophyllotoxin and analogues 8e or 8b. MCF-7 cells were treated for 6 h
indicated. Cells were incubated on ice for 30 min, some cells were then ﬁxed with 100%
rior to ﬁxation (bottom rows). Fixed cells were subjected to immunoﬂuorescence for a-
re imaged by confocal microscopy and representative images from three independent
, the reader is referred to the web version of this article.)
Fig. 7. Microtubule repolymerisation in the presence of podophyllotoxin, analogues 8e or 8b following cold-depolymerisation. MCF-7 cells were incubated on ice for 30 min, a
sample of “cold depolymerised” cells were then ﬁxed with 100% methanol at 20 C for 10 min (top row). The remaining cells were ﬁxed after being incubated for 30 min at 37 C
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(ArCH), 128.37 (ArC), 123.26 (ArCH), 122.57 (ArCH), 120.58 (ArC),
118.45 (ArCH), 116.26 (t, 1JC-F ¼ 255.9 Hz, CHF2), 104.08 (ArC), 81.93
(COH-9a), 74.55 (CH2-10), 50.06 (CH-12a), 35.77 (CH-13). HRMS
calcd for C24H17F2N3O4 (M þ H)þ, 450.1260; found, 452.1260.
4.1.1.13. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 9a-hydroxy-13-(2-
methyl-5-(triﬂuoromethoxy)phenyl)-9a,10,12a,13-tetrahydrofuro[3,4-
b]pyrido[3,2-f][1,10]phenanthrolin-12(9H)-one (8m). Yield: 61% 1H
NMR (500 MHz, DMSO-d6) d 9.14 (dd, J ¼ 1, 4 Hz, 1H, ArH), 8.94 (dd,
J ¼ 1.5, 8.5 Hz, 1H, ArH), 8.72 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 7.88 (dd,
J ¼ 4.5, 8.5 Hz, 1H, ArH), 7.56e7.52 (m, 2H, NH-9, ArH), 7.48e7.42
(m, 2H, ArH), 7.08 (d, J¼ 8.5 Hz, 1H, ArH), 6.66 (d, J¼ 2 Hz, 1H, ArH),
6.14 (s, 1H, OH-9a), 5.03 (s, 1H, CH-13), 4.59 (d, J ¼ 8 Hz, 1H, CH-10),
4.22 (d, J¼ 8.5 Hz,1H, CH-10), 3.51 (s, 1H, CH-12a), 2.67 (s, 3H, CH3);
19F NMR (DMSO-d6) d 56.96; 13C NMR (125 MHz, DMSO-d6)
d 174.45 (C]O), 149.78 (ArCH), 147.26 (ArC), 145.83 (ArC), 145.31
(ArCH), 142.93 (ArC), 141.30 (ArC), 136.32 (ArC), 134.44 (ArC), 132.08
(ArCH), 130.13 (ArCH), 128.06 (CF3), 129.54 (ArCH), 123.37 (ArCH),
122.68 (ArCH), 120.61 (ArC), 120.58 (ArC), 121.30 (ArCH), 118.75
(ArCH), 103.65 (ArC), 81.61 (COH-9a), 74.29 (CH2-10), 47.75 (CH-
12a), 33.23 (CH-13), 18.30 (ArCH3). MS (ESI): 482.1 [MþH]þ.
C26H20F3N3O4 calcd (C, 62.37; H, 3.77; N, 8.72); found (C, 61.98; H,
3.56; N, 8.91).
4.1.1.14. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 9a-hydroxy-13-(4-
(pentaﬂuoro sulfanyl)phenyl)-9a,10,12a,13-tetrahydrofuro[3,4-b]pyr-
ido[3,2-f][1,10] phenanthrolin-12(9H)-one (8n). Yield: 76% 1H NMR
(500 MHz, DMSO-d6) d 9.13 (dd, J ¼ 1.5, 4.5 Hz, 1H, ArH), 8.93 (dd,
J ¼ 1.5, 8.5 Hz, 1H, ArH), 8.73 (dd, J ¼ 1.5, 4.5 Hz, 1H, ArH), 7.92 (dd,
J ¼ 1.5, 8.5 Hz, 1H, ArH), 7.87 (dd, J ¼ 4, 8 Hz, 1H, ArH), 7.77 (d, J ¼ 9,
2H, ArH), 7.60 (s, 1H, NH-9), 7.53e7.47 (m, 3H, ArH), 6.16 (s, 1H, OH-
9a), 5.16 (s, 1H, CH-13), 4.59 (d, J ¼ 8.5 Hz, 1H, CH-10), 4.22 (d,
J ¼ 8.5 Hz, 1H, CH-10), 3.66 (s, 1H, CH-12a); 19F NMR (DMSO-d6)
d 87.97 (qn, J ¼ 150.9 Hz, 1F), 64.35 (d, J ¼ 150.4 Hz, 4F); 13C NMR
(125 MHz, DMSO-d6) d 174.14 (C]O), 149.79 (ArCH), 147.02 (ArC),
145.84 (ArC), 145.32 (ArCH), 141.15 (ArC), 135.74 (ArC), 134.94 (m,
ArC), 130.09 (ArCH), 129.67 (ArCH), 129.49 (ArCH), 128.26 (ArC),
125.68 (ArCH), 123.46 (ArCH), 122.67 (ArCH), 120.56 (ArC), 103.11
(ArC), 81.85 (COH-9a), 74.55 (CH2-10), 49.79 (CH-12a), 35.84 (CH-
13). MS (ESI): 510.1 [MþH]þ. C23H16F5N3O3S calcd (C, 54.23; H, 3.17;
N, 8.24); found (C, 53.96; H, 2.98; N, 8.42).
4.1.1.15. (9aS, 12aS, 13S) and (9aR, 12aR, 13R) 9a-hydroxy-13-(2-
methoxy-4-(triﬂuoromethoxy)phenyl)-9a,10,12a,13-tetrahydrofuro
[3,4-b]pyrido[3,2-f][1,10]phenanthrolin-12(9H)-one (8). Yield: 71%
1HNMR (500 MHz, DMSO-d6) d 9.17 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 8.96
(dd, J ¼ 1.5, 8.5 Hz, 1H, ArH), 8.77 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 7.90
(dd, J ¼ 4, 8.5 Hz, 1H, ArH), 7.68 (dd, J ¼ 1.5, 8.5 Hz, 1H, ArH),
7.56e7.52 (m, 2H, ArH, NH-9), 7.16 (d, J ¼ 2 Hz, 1H, ArH), 6.81 (d,
J¼ 8.5 Hz, 1H, ArH), 6.67 (d, J¼ 8.5 Hz,1H, ArH), 6.05 (s, 1H, OH-9a),
5.31 (s, 1H, CH-13), 4.62 (d, J ¼ 8 Hz, 1H, CH-10), 4.27 (d, J ¼ 8.5 Hz,
1H, CH-10), 4.10 (s, 3H, OCH3), 3.51 (s, 1H, CH-12a); 19F NMR
(DMSO-d6) d 56.58; 13C NMR (125 MHz, DMSO-d6) d 174.39 (C]O),
157.07 (ArC), 149.64 (ArCH), 149.12 (q, 2JC-F ¼ 30.5 Hz, ArC), 145.85
(ArC), 145.27 (ArCH), 141.27 (ArC), 136.02 (ArC), 130.55 (ArCH),
129.94 (ArCH), 129.09 (ArCH), 128.37 (CF3), 128.20 (ArC), 123.47
(ArCH), 122.59 (ArCH), 120.51 (ArC), 111.69 (ArCH), 104.45 (ArCH),
103.37 (ArC), 81.88 (COH-9a), 74.53 (CH2-10), 56.41 (OCH3), 47.59
(CH-12a), 30.64 (CH-13). HRMS calcd for: C25H18F3N3O5 (M þ H)þ,with 250 nM of the compounds (or the equivalent concentration of DMSO) as indicated. Fi
were counterstained with Hoechst (blue channel). Cells were imaged by confocal microsc
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the498.1257; found, 498.1271.
4.1.1.16. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 9a-hydroxy-13-((5-
methoxy-3,4-methylenedioxy)phenyl)-9a,10,12a,13-tetrahydrofuro
[3,4-b]pyrido[3,2-f][1,10]phenanthrolin-12(9H)-one (8p). Yield: 74%
1H NMR (500MHz, DMSO-d6) d 9.11 (dd, J¼ 1.5, 4 Hz,1H, ArH), 8.92
(dd, J ¼ 1.5, 8.5 Hz, 1H, ArH), 8.74 (dd, J ¼ 1.5, 4 Hz, 1H, ArH), 8.02
(dd, J ¼ 1, 8.5 Hz, 1H, ArH), 7.85 (dd, J ¼ 4, 8.5 Hz, 1H, ArH), 7.53 (dd,
J¼ 4, 8.5 Hz, 1H, ArH), 7.48 (s, 1H, ArH, NH-9), 6.74 (d, J¼ 1.5 Hz, 1H,
ArH), 6.35 (d, J ¼ 1.5 Hz, 1H, ArH), 6.06 (s, 1H, OH-9a), 5.90 (s, 1H,
OCH2O), 5.86 (s, 1H, OCH2O), 4.94 (s, 1H, CH-13), 4.57 (d, J ¼ 8.5 Hz,
1H, CH-10), 4.22 (d, J ¼ 8.5 Hz, 1H, CH-10), 3.78 (s, 3H, OCH3), 3.56
(s, 1H, CH-12a); 13C NMR (125 MHz, DMSO-d6) d 174.52 (C]O),
149.57 (ArCH), 148.06 (ArC), 145.54 (ArC), 145.03 (ArCH), 142.98
(ArC), 137.19 (ArC), 135.39 (ArC), 135.32 (ArC), 133.24 (ArC), 130.22
(ArCH), 130.13 (ArCH), 128.63 (ArC), 123.34 (ArCH), 122.64 (ArCH),
120.61 (ArC), 120.57 (ArC), 108.27 (ArCH), 104.34 (OCH2O), 102.48
(ArCH), 81.77 (COH-9a), 74.45 (CH2-10), 56.31 (OCH3), 50.28 (CH-
12a), 36.49 (CH-13). HRMS calcd for: C25H19N3O6 (M þ H)þ,
458.1347; found, 458.1338.
4.1.1.17. (9aS, 12aR, 13R) and (9aR, 12aS, 13S) 13-((3 ,4-
diﬂuoromethylenedioxy)phenyl)-9a-hydroxy-9a,10,12a,13-
tetrahydrofuro[3,4-b]pyrido[3,2-f][1,10]phenanthrolin-12(9H)-one
(8q). Yield: 77% 1H NMR (500 MHz, DMSO-d6) d 9.12 (dd, J ¼ 1.5,
4.5 Hz, 1H, ArH), 8.92 (dd, J ¼ 1.5, 8.5 Hz, 1H, ArH), 8.73 (dd, J ¼ 1.5,
4 Hz,1H, ArH), 7.97 (dd, J¼ 1.5, 8.5 Hz,1H, ArH), 7.85 (dd, J¼ 4, 8 Hz,
1H, ArH), 7.53 (s, 1H, NH-9), 7.50 (dd, J ¼ 4.5, 8.5 Hz, 1H, ArH), 7.32
(d, J ¼ 1.5 Hz, 1H, ArH), 7.24 (d, J ¼ 8.5 Hz, 1H, ArH), 7.10 (dd, J ¼ 2,
8.5 Hz, 1H, ArH), 6.07 (s, 1H, OH-9a), 5.09 (s, 1H, CH-13), 4.58 (d,
J ¼ 8.5 Hz, 1H, CH-10), 4.22 (d, J ¼ 8 Hz, 1H, CH-10), 3.61 (s, 1H, CH-
12a); 19F NMR (DMSO-d6) d 48.89.13C NMR (125 MHz, DMSO-d6)
d 174.24 (C]O), 149.72 (ArCH), 145.90 (ArC), 145.33 (ArCH), 142.56
(ArC), 141.24 (ArC), 141.19 (ArC), 139.27 (ArC), 135.56 (ArC), 131.11 (t,
1JC-F ¼ 254.3 Hz, CF2), 130.05 (ArCH), 129.72 (ArCH), 128.30 (ArC),
124.37 (ArCH), 123.39 (ArCH), 122.60 (ArCH), 120.56 (ArC), 110.32
(ArCH),109.58 (ArCH),103.67 (ArC), 81.92 (COH-9a), 74.56 (CH2-10),
50.08 (CH-12a), 36.09 (CH-13); HRMS calcd for: C24H15F2N3O5
(M þ H)þ, 464.1042; found, 464.1053.
4.2. X-ray crystal structure determination of compound 8c
Single-crystal XRD data were collected on an Agilent SupaNova
Dual Atlas diffractometer with a mirror monochromator using
either Cu (l ¼ 1.5418 Å) radiation and equipped with an Oxford
Cryosystems cooling apparatus. Crystal structures were solved and
reﬁned using SHELX. (Sheldrick, G. M. Acta Crystallogr., Sect. A
2008, 64, 112.) Non-hydrogen atoms were reﬁned with anisotropic
displacement parameters. Hydrogen atoms were inserted in
idealized positions, and a ridingmodel was usedwith Uiso set at 1.2
or 1.5 times the value of Ueq for the atom towhich they are bonded.
C24H16F3N3O4, FW ¼ 467.40, T ¼ 150(2) K, l ¼ 1.54184 Å, Mono-
clinic, P21/c, a ¼ 20.633(2) Å, b ¼ 6.0168(6) Å, c ¼ 18.8375(18) Å,
b¼ 115.552(12), V¼ 2109.9(4) Å3, Z¼ 4, r(calculated)¼ 1.471Mg/
m3, m ¼ 1.023 mm-1, Crystal size ¼ 0.238 x 0.031  0.020 mm3,
Reﬂections collected ¼ 8334, Independent reﬂections ¼ 4181,
R(int)¼ 0.0723, Parameters¼ 308, G-o-f¼ 1.015, Final R1¼0.0588,
wR2¼ 0.1111 on (I> 2s(I)), R1¼0.1240, wR2¼ 0.1404 on all data. In
the crystal structure, the molecules are linked by two types of
hydrogen bonds [N1eH1… O2 with geometry N… O ¼ 2.888(4) Å,xed cells were subjected to immunoﬂuorescence for a-tubulin (green channel). Nuclei
opy and representative images from three independent experiments are shown. (For
web version of this article.)
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Å, OeH… N ¼ 158.6)] to form layers parallel to the bc plane. CCDC
1426447 contains the supplementary crystallographic data for this
paper. The data can be obtained free of charge from The Cambridge
Crystallographic Data Centre via www.ccdc.cam.ac.uk/
getstructures.4.3. Docking study
We used the X-ray co-crystal structure of tubulin with podo-
phyllotoxin in the Protein Data Bank PDB ID: 1SA1 [23]. The protein
structure for the docking study was prepared with Protein Prepa-
ration Workﬂow in Schr€odinger software. Constrained energy
minimization was performed with the OPLS_2005 force ﬁeld.
Compounds (8a-q) were sketched in MOE (version 2014.09,
Chemical Computing Group Inc, Montreal, Quebec, www.
chemcomp.com. Canada) [24]. Molecular docking was performed
with Glide SP (version 9.5) in Maestro (Glide, version 9.5,
Schr€odinger, LLC, New York, NY. http://www. schrodinger.com)
[25]. The docking box was centred on the ligand of the crystal
structure. The molecule database used for docking was processed
with the LigPreP tool in Maestro. The best scoring poses of Glide-
Score were evaluated.4.4. Cell proliferation assay
A modiﬁed propidium iodide (PI) based monolayer assay [22]
was used to assess the anti-cancer activity of the compounds.
Brieﬂy, cells were harvested from exponential phase cultures,
counted and plated in 96-well ﬂat-bottommicrotiter plates at a cell
density of 8.000e12.000 cells/well. After a 24 h recovery period to
allow the cells to resume exponential growth, 10 ml of culture
medium (six control wells/plate) or culture medium with test
compound were added. The compounds were applied in half-log
increments at 10 concentrations in triplicate. After a total treat-
ment period of 96 h, cells were washed with 200 ml PBS to remove
dead cells and debris. Then, 200 ml of a solution containing 7 mg/mL
propidium iodide (PI) was added. After an incubation period of
1e2 h at room temperature, ﬂuorescence (FU) was measured using
the EnSpire Multimode Plate Reader (excitation l ¼ 530 nm,
emission l ¼ 620 nm) to quantify the amount of attached viable
cells. IC50 values were calculated by 4-parameter non-linear curve
ﬁt using OncotestWarehouse Software. For calculation of mean IC50
values the geometric mean was used.4.5. Subcellular analysis of microtubule organisation
4.5.1. Chemicals and reagents
Podophyllotoxin and 8e and 8b were dissolved in DMSO to
produce a stock concentration of 2.5 mM and stored at 4 C. DMSO
and the anti-a-tubulin antibody (#T9026) were from Sigma-
eAldrich (Dorset, UK). RPMI 1640, FBS, the nuclear probe Hoechst
33342 and Alexa-488 conjugated anti-mouse antibody (#A-21200)
were from Life Technologies (Paisley, UK).4.5.2. Cell culture
MCF-7 cells were maintained in RPMI 1640 supplemented with
10% FBS (complete media). The cells were obtained from ATCC and
routinely tested for mycoplasma infection. For immunoﬂuores-
cence experiments: 180,000 cells were seeded onto glass coverslips
in 12-well plates and cultured to 70e80% conﬂuency at 37 C/5%
CO2 in complete media.4.5.3. Microtubule immunoﬂuorescence assay: cell culture and
treatments
Following cell seeding (42 h) the media was replaced with fresh
complete media containing 250 nM of podophyllotoxin, compound
8e and 8b or 0.01% DMSO. The cells were treated for 6 h with drug
or diluent control then subjected to downstream immunoﬂuores-
cence analysis (see tubulin immunoﬂuorescence protocol).
4.5.4. Microtubule repolymerisation assay: cell culture and
treatments
4.5.4.1. First variation, pre-treatment. Following cell seeding (42 h)
the media was replaced with drug (or diluent control) containing
complete media and cells were treated for 6 h with 250 nM of
podophyllotoxin, compound 8e, 8b or 0.01% DMSO. The plates were
then placed on ice and cells were incubated at 4 C for 30 min to
depolymerise the tubulin cytoskeleton [27,28,30]. One set of cover
slips for each treatment condition was prepared for tubulin
immunoﬂuorescence (see protocol below) and the remaining sets
of cover slips were returned to the incubator (37 C, 5% CO2) for
30 min to allow re-polymerisation of microtubules. Tubulin
immunoﬂuorescence was performed after the cells had been
rewarmed for 30 min (see below).
4.5.4.2. Second variation, no pre-treatment. Following cell seeding
(42 h), the plates were placed on ice for 30 min to cold-
depolymerise the tubulin cytoskeleton. Control cold-
depolymerised coverslips were then immediately prepared for
tubulin immunoﬂuorescence and the remaining coverslips were
rewarmed and treated with 250 nM of podophyllotoxin, compound
8e, 8b or 0.01% DMSO for 30 min (37 C, 5% CO2). Together with the
controls thesewere then subjected to tubulin immunoﬂuorescence.
4.5.5. Tubulin immunoﬂuorescence
The media was aspirated and the cells were washed once in ice-
cold PBS before being ﬁxed in 100% methanol at 20 C for 10 min.
The cells were then washed thrice in PBS and stored overnight at
4 C. The following day cells were incubated in 150 mL of blocking
solution (2% FBS [v/v], 2% BSA [w/v] in PBS pH 7.4) for 30 min.
Blocking was followed by 1 h incubationwith 100 ml of mouse anti-
a tubulin antibody diluted 1:2000 in blocking solution. Cells were
then washed 3  5min in PBS before being incubated with
Alexa488 labelled, anti-mouse secondary antibody (1:400) and
Hoechst 33342 (1 mg/ml) for 30 min. The cells were washed a ﬁnal
3  5 min in PBS before coverslips were dipped once into PBS, once
into dH2O and mounted onto glass slides with 12 mL of mounting
medium (Dako oil). Three independent experiments were carried
out in duplicate.
4.5.6. Confocal microscopy
Confocal ﬂuorescence microscopy analysis was conducted on a
Leica SP5 inverted confocal laser scanning microscope. The mi-
croscope was equipped with a 63x oil-immersion objective and the
405 and 488 nm lasers were used. Gain and offset settings were
optimised for each ﬂuorescent channel within an experiment. Im-
ages were recorded using the sequential scanning mode to prevent
ﬂuorescence channel crosstalk/bleed-through. Images were scan-
ned at 100 Hz with a line average of three to reduce noise.
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